Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;10(3):367-380.
doi: 10.1016/j.jacbts.2024.12.010. Epub 2025 Feb 5.

Inhibition of Soluble Epoxide Hydrolase Reduces Inflammation and Myocardial Injury in Arrhythmogenic Cardiomyopathy

Affiliations

Inhibition of Soluble Epoxide Hydrolase Reduces Inflammation and Myocardial Injury in Arrhythmogenic Cardiomyopathy

Dipak Panigrahy et al. JACC Basic Transl Sci. 2025 Mar.

Abstract

We analyzed the role of pro- and anti-inflammatory eicosanoids in the pathogenesis of arrhythmogenic cardiomyopathy (ACM). Lipidomics revealed reduced levels of anti-inflammatory oxylipins in plasma and increased levels of pro-inflammatory eicosanoids in hearts of Dsg2mut/mut mice, a preclinical model of ACM. Disease features were reversed in vitro in rat ventricular myocytes expressing mutant JUP by the anti-inflammatory epoxyeicosatrienoic acid 14-15-EET, whereas 14,15-EEZE, which antagonizes the 14,15-EET receptor, intensified nuclear accumulation of the desmosomal protein plakoglobin. Inhibition of soluble epoxide hydrolase (sEH), an enzyme that converts anti-inflammatory EETs into polar, less active diols, prevented progression of myocardial injury in Dsg2mut/mut mice and promoted recovery of contractile function. This was associated with reduced myocardial expression of genes involved in innate immune signaling and fewer injurious macrophages expressing CCR2. These results suggest that pro-inflammatory eicosanoids contribute to the pathogenesis of ACM. Inhibition of sEH may be an effective, mechanism-based therapy for ACM patients.

Keywords: lipidomics; oxylipins; pro-inflammatory eicosanoids.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures This work was supported by NIH grants R01HL148348 (JES) and 1R01CA276107 (Dr Panigrahy), and by the Credit Unions Kids at Heart and the Carter Joseph Buckley Pediatric Brain Tumor Fund (Dr Panigrahy). Partial support was provided by NIH – NIEHS (RIVER Award), R35 ES030443-01, NIH-NINDS U54 NS127758 (Counter Act Program), and NIH – NIEHS (Superfund Award) P42 ES004699 (all to Dr Hammock). Additional support came from a Washington University in St. Louis Rheumatic Diseases Research Resource-Based Center grant (NIH P30AR073752, Dr Lavine), a National Institutes of Health grant (R35 HL161185, Dr Lavine), a Leducq Foundation Network grant (#20CVD02, Dr Lavine), a Burroughs Welcome Fund grant (1014782, Dr Lavine), a Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital grant (CH-II-2015-462, CH-II-2017-628, PM-LI-2019-829, Dr Lavine), a Foundation of Barnes-Jewish Hospital grant (8038-88, Dr Lavine), and gifts from Washington University School of Medicine (Dr Lavine). Dr Penna was supported by an NIH grant (5Tr32AI007163-44). Additional support came from a British Heart Foundation grant (PG/18/27/33616 to Dr Asimaki). This work was also supported, in part, by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES025034 to Dr Zeldin). Dr Yang is a part-time employees of EicOsis Human Health. Dr Hwang is a part-time employees of EicOsis Human Health and is an inventor of a patent related to this study. Dr Lavine is a consultant for Kiniksa, Cytokinetics, Implicit Bioscience, and SUN Pharmaceuticals. Dr Hammock holds patents related to the commercial development of soluble epoxide hydrolase inhibitors for cardiovascular disease; is Chief Scientific Officer of EicOsis Human Health, currently conducting human 1b safety trials of the soluble epoxide hydrolase inhibitor EC5026; and is an inventor of a patent related to this study. Dr Saffitz is a consultant for Implicit Bioscience, Rocket Pharmaceuticals and Rejuvenate Bio and is an inventor of a patent related to this study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

None
Graphical abstract
Figure 1
Figure 1
Lipidomics Assays and Expression of Endoplasmic Reticulum Stress Genes in Dsg2mut/mut Mice (A) Free oxlipin levels in plasma and hearts from wild-type (WT) and Dsg2mut/mut mice at ages 8 or 16 weeks quantified by liquid chromatography/tandem mass spectrometry; n = 5-9, ∗P < 0.05 vs WT. Heart oxylipins are displayed in a volcano plot of Log2 fold relative concentration. Oxylipins above the dashed line represent significant differences between WT and Dsg2mut/mut mice. (B) quantitative polymerase chain reaction showing increased expression of the endoplasmic reticulum chaperone gene BiP and the protein folding protein disulfide isomerase gene Pdi, both markers of endoplasmic reticulum stress. Gene expression values in WT samples were normalized to 1; values in Dsg2mut/mut samples are shown as relative levels; ∗P < 0.05 vs WT by t-test.
Figure 2
Figure 2
Effects of 14,15-EET and its Antagonist on ACM Features In Vitro Effects of 14,15-eicosatrienoic acid (14,15-EET) and 14,15-eicosa-5(Z)-enoic acid (14,15-EEZE) on the distribution of immunoreactive signals for plakoglobin, connexin43 (Cx43), and RelA/p65 in primary cultures of wild-type (WT) neonatal rat ventricular myocytes and myocytes transfected to express the arrhythmogenic cardiomyopathy disease allele JUP2157del2.
Figure 3
Figure 3
Uniform Manifold Approximation and Projection Plots Showing Populations of Cells Isolated From Hearts of 16-Week-Old Dsg2mut/mut Mice and Relative Density of Ephx2 Expression in Each Population sEH (Ephx2) is expressed mainly in cardiac myocytes in the heart with lower levels of expression in endothelial cells.
Figure 4
Figure 4
Effects of sEH Inhibition on ACM Features In Vitro Effects of 1μM TPPU (1-trifluoro-methoxy-phenyl-3-(1-propionylpiperidin-4-yl) urea) and 500 nM PTUPB (4-(5-phenyl-3-{3-[3-(4-trifluoromethylphenyl)-ureido]-propyl}-pyrazol-1-yl)-benzenesulfonamide) on the distribution of immunoreactive signals for plakoglobin, connexin43 (Cx43), and RelA/p65 in primary cultures of wild-type (WT) neonatal rat ventricular myocytes and myocytes transfected to express the arrhythmogenic cardiomyopathy disease allele JUP2157del2.
Figure 5
Figure 5
Effects of sEH Inhibition on Contractile Function in Dsg2mut/mut Mice Effects of TPPU (1-trifluoro-methoxy-phenyl-3-(1-propionylpiperidin-4-yl) urea) on left ventricular ejection fraction (A) and fractional shortening (B) in wild-type (WT) and Dsg2mut/mut mice. (C) Representative echocardiograms at the follow-up time point after treatment. Baseline echocardiography was performed in 9-week-old mice and then repeated after treatment for 4 weeks with TPPU or vehicle (Veh). Data are shown for each group (left) and each individual animal (right). The Shapiro-Wilk test was used to assess normality within each of the 4 groups. No significant deviations from normality were found, indicating an approximate normal distribution. Then, Tukey’s 1-way analysis of variance was used. ∗∗∗∗P < 0.0001 Dsg2mut/mut + Vehicle follow-up vs Dsg2mut/mut + TPPU follow-up. Data are shown as mean with SEM.
Figure 6
Figure 6
Effects of sEH Inhibition on Fibrosis and CCR2+ Cells in Heart of Dsg2mut/mut Mice Effects of TPPU (1-trifluoro-methoxy-phenyl-3-(1-propionylpiperidin-4-yl) urea) on the amount of myocardial fibrosis (A) and the number of cells expressing CCR2 (B) in wild-type (WT) and Dsg2mut/mut mice (positive cells identified by arrows in representative immunostained tissue sections). Hearts were excised from animals after treatment for 4 weeks with TPPU or vehicle (Veh) and analyzed by histology in trichrome stained sections or by immunohistochemistry in sections stained with an anti-CCR2 antibody. The Shapiro-Wilk test was used to assess normality within each of the 4 groups. No significant deviations from normality were found, indicating an approximate normal distribution. Then, Tukey’s 1-way analysis of variance was used. ∗P < 0.05 WT vs vehicle-treated Dsg2mut/mut; ∗P < 0.05 vehicle-treated Dsg2mut/mut vehicle-treated vs 1770-treated Dsg2mut/mut mice. Data are shown as mean with SEM.
Figure 7
Figure 7
Effects of sEH Inhibition on Expression of Innate Immune Signaling Genes Effects of TPPU (1-trifluoro-methoxy-phenyl-3-(1-propionylpiperidin-4-yl) urea) on expression of Tnfα, Tlr4, and Ccr2 in hearts of wildtype (WT) and Dsg2mut/mut mice treated with TPPU or vehicle (Veh). Gene expression values in wildtype samples treated with vehicle were normalized to 1; values in all other groups are shown as relative levels. The Shapiro-Wilk test was used to assess normality within each of the 4 groups. No significant deviations from normality were found, indicating an approximate normal distribution. All tests were 1-way analysis of variance. ∗P < 0.05 Dsg2mut/mut vs WT Veh; ∗P < 0.05 Dsg2mut/mut vs Dsg2mut/mut + TPPU. Data are shown as mean with SEM.

Update of

References

    1. Corrado D., Link M., Calkins H. Arrhythmogenic right ventricular cardiomyopathy. New Eng J Med. 2017;376:61–72. - PubMed
    1. Corrado D., Basso C., Thiene G., et al. Spectrum of clinico-pathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512–1520. - PubMed
    1. Chelko S.P., Penna V., Engle M., et al. NFĸB signaling drives myocardial injury via CCR2+ macrophages in a preclinical model of arrhythmogenic cardiomyopathy. J Clin Invest. 2024;134(13) doi: 10.1172/JCI183441. - DOI - PMC - PubMed
    1. Chelko S.P., Asimaki A., Lowenthal J., et al. Therapeutic modulation of the immune response in arrhythmogenic cardiomyopathy. Circulation. 2019;140:1491–1505. - PMC - PubMed
    1. Hawthorne R.N., Blazeski A., Lowenthal J., et al. Altered electrical, biomolecular, and immunologic phenotypes in a novel patient-derived stem cell model of desmoglein-2 mutant ARVC. J Clin Med. 2021;10(14):3061. doi: 10.3390/jcm10143061. - DOI - PMC - PubMed

LinkOut - more resources